Copyright
©2008 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Mar 21, 2008; 14(11): 1720-1733
Published online Mar 21, 2008. doi: 10.3748/wjg.14.1720
Published online Mar 21, 2008. doi: 10.3748/wjg.14.1720
Tumor suppressor and hepatocellular carcinoma
Juliette Martin, Jean-François Dufour, Department of Clinical Pharmacology, Bern, CH-3010, Switzerland
Correspondence to: Juliette Martin, PhD, Department of Clinical Pharmacology, University of Bern, Murtenstrasse, 35, CH-3010 Bern, Switzerland. juliette.martin@ikp.unibe.ch
Telephone: +41-31-6322595
Fax: +41-31-6324997
Received: July 20, 2007
Revised: November 14, 2007
Published online: March 21, 2008
Revised: November 14, 2007
Published online: March 21, 2008
Abstract
A few signaling pathways are driving the growth of hepatocellular carcinoma. Each of these pathways possesses negative regulators. These enzymes, which normally suppress unchecked cell proliferation, are circumvented in the oncogenic process, either the over-activity of oncogenes is sufficient to annihilate the activity of tumor suppressors or tumor suppressors have been rendered ineffective. The loss of several key tumor suppressors has been described in hepatocellular carcinoma. Here, we systematically review the evidence implicating tumor suppressors in the development of hepatocellular carcinoma.
Keywords: Tumor suppressor, Hepatocellular carcinoma, Deregulation, Liver, Carcinogenesis